Phase II study of FOLFOX plus regorafenib (REGO) in patients with unresectable or metastatic esophagogastric (EG) cancer Meeting Abstract
| Authors: | Janjigian, Y. Y.; Ku, G. Y.; Chou, J. F.; Capanu, M.; Siebel, M.; Chalasani, S. B.; Boyar, M. S.; Goldberg, Z.; Desai, A. M.; Kelsen, D. P.; Imtiaz, T.; Ilson, D. H. |
| Abstract Title: | Phase II study of FOLFOX plus regorafenib (REGO) in patients with unresectable or metastatic esophagogastric (EG) cancer |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036900892 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.4053 |
| Notes: | Meeting Abstract: 4053 -- Source: Wos |
